undamentalytics Newsletter
Sign in

Repligen Corp cash flow statement

In fiscal 2025, Repligen Corp's operations generated $117m of cash; it spent $23.5m on capital projects, leaving free cash flow of $93.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Mar 20102011Mar 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−2313261815817336763119172114175117130
Depreciation and amortisation124345511162127385169707978
Stock-based pay1—112457101317282726483334
Capital spending11156345111922678536262423
Free cash flow−331221131231222494052877815094107
Free cash flow after stock pay−4—1120119−151236232460521026173
Share buybacks———————————001400—
Shares issued———————129—32129800————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NEO vs RGENRGEN vs TXGAZTA vs RGENRGEN vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Repligen Corp's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Repligen Corp.